Diagnostic benefits of mindin as a prostate cancer biomarker: Dijagnostičke prednosti mindina kao biomarkera raka prostate.,Journal of Medical Biochemistry

当前位置： X-MOL 学术 › J. Med. Biochem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Diagnostic benefits of mindin as a prostate cancer biomarker: Dijagnostičke prednosti mindina kao biomarkera raka prostate.
Journal of Medical Biochemistry ( IF 2.0 ) Pub Date : 2020-01-10 , DOI: 10.2478/jomb-2019-0008
Lenka Hanousková ₁ , Jakub Řezáč ₂ , Štěpán Veselý ₂ , Richard Průša ₁ , Karel Kotaška ₁

Affiliation

BACKGROUND It has been shown that decreased expression and activity of extracellular matrix protein mindin correlate with various types of cancers including breast, colon and lung cancers. The aim of the presented study was to investigate the serum mindin levels in prostate cancer. METHODS Mindin concentrations in serum were measured in 56 patients with prostate cancer (mean age 68 years) and in control group of 29 healthy men (mean age 64 years) using commercially available enzymatic immunoassay (Cusabio, WuHan, China). The patients were divided with respect to the severity of the disease into two groups according to the EAU guidelines (stage 1, 2 - less severe tumours, stage 3, 4 - severe tumours). RESULTS Serum mindin concentrations were significantly elevated in the group of healthy individuals unlike in the patients with prostate cancer (2.12 ng/mL vs 0.78 ng/mL, with P=0.0007, AUC=0.705). Patients with less severe tumours (stage 1, 2) and severe tumours (stage 3, 4) had significantly decreased levels of S-mindin as well (P=0.0037), although the difference in serum mindin concentrations between the patients with less severe and severe tumours was not significant. CONCLUSIONS Concentrations of mindin were decreased in patients with prostate cancer and reduced in patients with less severe prostate cancer as well. Mindin appears to be a promising diagnostic marker useful in the diagnosis of prostate cancer. UVOD Pokazalo se da je smanjena ekspresija i aktivnost ekstracelularnog proteinskog matriksa mindina korelira sa različitim tipovima raka, uključujući rak dojke, debelog creva i pluća. Cilj prikazane studije je bio da se ispita serumski nivo mindina kod karcinoma prostate. METODE Koncentracije mindina u serumu su merene kod 56 bolesnika sa karcinomom prostate (srednja starost 68 godina) i u kontrolnoj grupi od 29 zdravih muškaraca (srednja starost 64 godine) korišćenjem komercijalno dostupnog enzimskog testa (Cusabio, VuHan, Kina). Pacijenti su prema težini bolesti podeljeni u dve grupe prema EAU smernicama (faza 1, 2 - manje teški tumori, faza 3, 4 - teški tumori). REZULTATI Koncentracije serumskog mindina bile su značajno povišene u grupi zdravih pojedinaca, za razliku od pacijenata sa rakom prostate (2,12 ng/mL u odnosu na 0,78 ng/mL, sa P=0,0007, AUC=0,705). Pacijenti sa manje ozbiljnim tumorima (faza 1, 2) i teškim tumorima (faza 3, 4) imali su i značajno snižene nivoe S-mindina (P=0,0037), iako razlika u koncentracijama mindina u serumu izme u pacijenata sa manje teškim i ozbiljnim tumori nije bila značajna. ZAKLJUČAK Koncentracije mindina su smanjene kod pacijenata sa rakom prostate, a smanjene su i kod pacijenata sa manje teškim oblikom raka prostate. Izgleda da je mindin obećavajući dijagnostički marker i da je koristan u dijagnostici raka prostate.

更新日期：2020-01-10

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11